The company will receive an upfront payment of Euro 100 million (Rs. 880 crores) for product development and site approval from European authorities
The segment has immense growth potential driven by the country's increasing healthcare needs, technological innovations, government support, and emerging market opportunities
Indoco is comprehensively working on the remedial action plan
This is used to treat central diabetes insipidus and bedwetting
India's bio economy has experienced remarkable growth, skyrocketing from US $10 billion in 2014 to over $130 billion in 2024, with projections to reach $300 billion by 2030
These digital initiatives are expected to enhance the accessibility and efficiency of drug safety monitoring and standards compliance
Enhanced collaboration under the Memorandum of Cooperation (MoC) between India and Japan in medical product regulations
The academy has secured partnerships with 15 esteemed hospitals
mRESVIA is Moderna's second approved product and the only RSV vaccine available in single-dose pre-filled syringes
GAAP net loss of $1.2 billion and GAAP diluted EPS of $(3.07)
Subscribe To Our Newsletter & Stay Updated
